Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Chief Financial Officer | December 22, 2025 | December 29, 2025 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Chief Financial Officer | September 16, 2020 | September 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date December 22, 2025 · Filed December 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,758 |
Reported balance
After 2025-12-22 transaction · row 1
1 source rowRow 1 · 2025-12-22 · Grant · Acquired 26,758 · Balance 26,758 F1: The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.
Intec Pharma Ltd.
Report date September 16, 2020 · Filed September 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2027-09-16 | Direct | 100,000 |
Reported balance
After 2020-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-16 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests and becomes exercisable in full on December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in full on December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2025 Filed Dec 29, 2025 16:01 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock | 26,758 | $2.03 | $54,318.74 |
DisclosureSEC source: 0001493152-25-029356 · ownership.xml · nonDerivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,758 F1 · shares: The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 1,125 | $0.07 Strike: $610.24 | $79.88 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 7 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2026-01-22 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 41 | $0.07 Strike: $331.20 | $2.91 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 6 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41 shares Expires 2026-03-27 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.07 Strike: $357.28 | $35.50 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 5 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2026-07-25 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.07 Strike: $357.28 | $35.50 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 4 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2026-07-25 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | $0.07 Strike: $72.00 | $177.50 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 3 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-09-13 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 1,125 | $0.07 Strike: $34.32 | $79.88 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 2 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2027-02-17 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 1,250 | $0.07 Strike: $25.72 | $88.75 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2027-09-16 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 16:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-24-040729 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-10-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-24-003445 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 16:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001493152-23-002020 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 16:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001493152-22-005611 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on February 25, 2023 and thereafter the remaining shares vest and become exercisable in equal quarterly installments over the following 24 months. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 17:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001493152-21-018906 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2026-08-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable over a period of twelve months in four equal quarterly installments and accelerate upon termination of Mr. Sassi's consulting agreement with Indaptus Therapeutics, Inc. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 17:02 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001213900-20-027396 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2027-09-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in full on December 31, 2021. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:46 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-20-004343 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 90,000 shares Expires 2027-02-17 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on February 17, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through February 17, 2023. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 21:32 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001213900-19-018237 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on September 13, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through September 13, 2022. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 16:11 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001213900-19-001104 · ownership.xml · derivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 90,000 shares Expires 2026-01-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through January 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.